


**Supplemental information**


**METTL14-dependent m<sup>6</sup>A modification controls**

**iNKT cell development and function**

**Liang Cao, Eva Morgun, Samantha Genardi, Lavanya Visvabharathy, Yongyong Cui, Haochu Huang, and Chyung-Ru Wang**





**Figure S1. Mettl14-deficiency impaired development of various T cell subsets in the thymus and peripheral. Related to Figure 1.** (A) Cell number of DP, CD4<sup>SP</sup>, CD8<sup>SP</sup> and DN in thymus. (B) Cell number of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in spleen. (C) Gating strategy of type II NKT cells in the liver of B6 mice. (D) Gating strategy of MAIT cells. (E) Representative FACS plot of type II NKT cells in thymus and liver. (F) Representative plot of MAIT cells in thymus and liver. Cell number of type II NKT cells and MAIT cells in thymus (G) and liver (H) (n=6-7). SEM is shown. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.




**Figure S2.** The expression of Egr2 was not altered in T-Mettl14<sup>-/-</sup> mice. Related to

**Figure 3.** **(A)** Histogram of Egr2 expression in DP thymocytes and thymic iNKT in T-Mettl14<sup>-/-</sup> mice. **(B)** Bar graph of MFI of Egr2 in DP thymocytes and thymic iNKT in T-Mettl14<sup>-/-</sup> mice (n=3). SEM is shown. n.s., not significant.

**A****B**


**Figure S3. Heat map of GSEA core enriched genes. Related to Figure 4.** (A) P53 pathway. (B) Apoptosis pathway.




**Figure S4. Expression of *Socs* family genes in T-Mettl14<sup>-/-</sup> DP thymocytes**

**and Mettl14<sup>KD</sup> DN32.D3 NKT cell hybridomas. Related to Figure 6 and 7.**

(A) The expression of *Socs1*, *Socs2* and *Socs3* was not altered in T-Mettl14<sup>-/-</sup> DP thymocytes. (n=6) (B) Increased expression of *Socs1*, *Socs2* and *Socs3* in *Mettl14<sup>KD</sup>* DN32.D3 (n=5-6). SEM is shown. \*P < 0.05; \*\*P < 0.01.



**Figure S5. Expansion of splenic iNKT cells was impaired in T-Mettl14<sup>-/-</sup> mice after *in vivo*  $\alpha$ -GalCer injection. Related to Figure 7.** (A) Representative dot plots of splenic iNKT cells in WT and T-Mettl14<sup>-/-</sup> mice at D3 after injection with  $\alpha$ -GalCer (IV). (B and C) Quantification of percentage and absolute cell number of splenic iNKT cells in WT and T-Mettl14<sup>-/-</sup> mice. (D) Percentage of Annexin V<sup>+</sup> in splenic iNKT cells. (E) Percentage of Ki67<sup>+</sup> in splenic iNKT cells. (n=4). SEM is shown. \*P < 0.05; \*\*\*P < 0.001.



**Figure S6. GSEA analysis of RNAseq data from WT and T-Mettl14<sup>-/-</sup> DP thymocytes. Related to Figure 4.** (A) Myc signaling pathway. (B) Notch signaling pathway. (C) Inflammation response.